© Reuters. Vials of AstraZeneca’s COVISHIELD, coronavirus disease (COVID-19) vaccine are seen inside a visual inspection machine inside a lab at the Serum Institute of India, Pune
(Reuters) – AstraZeneca (NASDAQ:) Plc will acquire U.S. based Alexion Pharmaceuticals (NASDAQ:) in a $39 billion deal, the company said in a statement on Saturday.
Alexion shareholders will receive $60 in cash and 2.1243 AstraZeneca American Depositary Shares per Alexion share, the company said.
Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.